New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 5, 2012
10:01 EDTADT, BSMX, KYTH, ANFI, WDAY, RGLS, ICPT, AMBA, SSTK, MUSA, CHTROn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: ADT Corp. (ADT) initiated with a Buy at Citigroup... Ambarella (AMBA) initiated with a Buy at Deutsche Bank... Amira Nature Foods (ANFI) initiated with a Buy at Deutsche Bank... Charter (CHTR) initiated with an Underweight at Barclays... Intercept Pharmaceuticals (ICPT) initiated with a Buy at Needham... Kythera Biopharmaceuticals (KYTH) initiated with a Neutral at Goldman... Metals USA (MUSA) initiated with an Outperform at Wells Fargo... Regulus Therapeutics (RGLS) initiated with a Buy at Needham... Santander Mexico (BSMX) initiated with a Buy at Citigroup... Shutterstock (SSTK) initiated with a Buy at Jefferies... Workday (WDAY) initiated with a Buy at Canaccord.
News For ADT;AMBA;ANFI;CHTR;ICPT;KYTH;MUSA;RGLS;BSMX;SSTK;WDAY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
January 23, 2015
09:12 EDTANFIAmira Nature Foods management to meet with Oppenheimer
Subscribe for More Information
09:07 EDTKYTHKythera announces FDA advisory committee to review ATX-101 on March 9
Kythera announced the Dermatology and Ophthalmic Drugs Advisory Committee of the FDA is scheduled to review Kythera's New Drug Application, or NDA, for ATX-101 for improvement in the appearance of moderate to severe submental fullness in a half-day meeting on the morning of March 9. The date and details of the meeting are subject to confirmation by the FDA in a Federal Register notice. Kythera submitted the ATX-101 NDA to the FDA on May 12, 2014. The NDA will be subject to a standard review and has a Prescription Drug User Fee Act, or PDUFA, action date of May 13. The PDUFA date is the goal date for the FDA to complete its review of the NDA.
January 22, 2015
16:28 EDTWDAYWorkday initiated with an Outperform at Cowen
Subscribe for More Information
07:17 EDTICPTIntercept price target lowered to $300 from $500 at Deutsche Bank
Subscribe for More Information
January 21, 2015
10:01 EDTBSMXOn the Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Ashford Hospitality (AHT) upgraded to Outperform from Neutral at Credit Suisse... BAE Systems (BAESY) upgraded to Buy from Neutral at Goldman... Bazaarvoice (BV) upgraded to Outperform from Market Perform at Cowen... Becton Dickinson (BDX) upgraded to Outperform at Cowen... CVS Health (CVS) upgraded to Buy from Neutral at Goldman... Camden Property (CPT) upgraded to Outperform from Neutral at Credit Suisse... ConocoPhillips (COP) upgraded to Buy from Neutral at BofA/Merrill... Cornerstone OnDemand (CSOD) upgraded to Buy from Neutral at DA Davidson... Cree (CREE) upgraded to Overweight at Stephens... DDR Corp. (DDR) upgraded to Outperform from Neutral at Credit Suisse... EastGroup Properties (EGP) upgraded to Outperform from Neutral at Credit Suisse... Energy Transfer Partners (ETP) upgraded to Outperform from Neutral at Credit Suisse... Esperion (ESPR) upgraded at BofA/Merrill... Exxon Mobil (XOM) upgraded to Outperform from Market Perform at Wells Fargo... FXCM (FXCM) upgraded to Market Perform from Underperform at Keefe Bruyette... Fair Isaac (FICO) upgraded to Overweight from Equal Weight at Barclays... Golar LNG (GLNG) upgraded to Buy from Hold at Nordea... Gran Tierra (GTE) upgraded to Buy at Canaccord... Host Hotels (HST) upgraded to Outperform from Neutral at Credit Suisse... J.M. Smucker (SJM) upgraded to Overweight from Neutral at JPMorgan... Kilroy Realty (KRC) upgraded to Neutral from Underperform at Credit Suisse... Level 3 (LVLT) upgraded to Outperform from Market Perform at Wells Fargo... Lowe's (LOW) upgraded to Overweight from Equal Weight at Morgan Stanley... Michael Kors (KORS) upgraded to Outperform at Cowen... Netflix (NFLX) upgraded at Nomura... Regions Financial (RF) upgraded to Buy from Neutral at Guggenheim... Ruckus Wireless (RKUS) upgraded to Outperform from Market Perform at Northland... Santander Mexico (BSMX) upgraded to Neutral from Underperform at Credit Suisse... Scorpio Tankers (STNG) upgraded to Buy at Canaccord... Sprouts Farmers Markets (SFM) upgraded to Buy from Neutral at BofA/Merrill... Strategic Hotels (BEE) upgraded to Outperform from Neutral at Credit Suisse... The Medicines Co. (MDCO) upgraded to Outperform from Market Perform at Leerink... Whole Foods (WFM) upgraded at Sterne Agee... Wolseley (WOSYY) upgraded to Neutral from Underperform at Exane BNP Paribas.
09:09 EDTANFIAmira Nature Foods weakness creates buying opportunity, says KeyBanc
Subscribe for More Information
08:06 EDTWDAYWorkday continues European expansion with plans for Germany
Workday unveiled its plans to provide products for German customers as it continues its European expansion. Workday invested significant resources to engineer its suite of applications to meet the needs of the German business market, including the various aspects of collaborating with the German works councils and local data protection and privacy directives, as well as the important functional aspects of dealing with German vacation plans, overtime regulations, tariffs, and collective bargaining agreements. Workday also announced today that services partners including Accenture, DayNine Consulting, Deloitte, HP, IBM, Promerit/ realright and PwC have established Workday deployment practices in Germany. Workday now has a total of seven offices across Europe including Amsterdam, The Netherlands; Belfast, UK; Munich, Germany; Dublin, Ireland; London, UK; Paris, France; and Stockholm, Sweden as well as regional data centers in Dublin and Amsterdam.
07:50 EDTBSMXSantander Mexico upgraded to Neutral from Underperform at Credit Suisse
January 20, 2015
07:15 EDTWDAYSAP not interested in buying competitors Workday, Salesforce, Bloomberg reports
Subscribe for More Information
January 15, 2015
06:07 EDTSSTKShutterstock to acquire PremiumBeat for $32M in cash
Shutterstock has entered into a definitive agreement to acquire PremiumBeat, a provider of exclusive, high-quality music and sound effects for use in videos, films, television, apps, games, and other creative projects. With offices in Montreal and Dallas, PremiumBeat will continue under the leadership of Francois Arbour, who will expand his responsibilities to lead music globally for Shutterstock and focus on further growth. The purchase price consists of initial consideration of approximately $32M in cash. Additional consideration is payable upon the achievement of certain operating and financial goals through 2018. The company expects to update its 2015 financial outlook for the impact of this transaction when it reports Q4 earnings.
06:06 EDTSSTKShutterstock to acquire Rex Features for $33M
Shutterstock has entered into a definitive agreement to acquire Rex Features, the largest independently owned photographic press agency in Europe. The purchase price is approximately $33M, substantially all of which will be paid in cash. The company expects to update its 2015 financial outlook for the impact of this transaction when it reports Q4 earnings.
January 13, 2015
10:43 EDTANFIAmira Nature Foods mentioned cautiously by TheStreetSweeper
Reference Link
07:11 EDTRGLSRegulus Therapeutics management to meet with Deutsche Bank
Subscribe for More Information
January 12, 2015
10:00 EDTCHTROn The Fly: Analyst Initiation Summary
Subscribe for More Information
10:00 EDTADTOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:13 EDTICPTIntercept plans to initiate PSC Program Biliary Atresia Phase in 2H15
Intercept provided a clinical update on obeticholic acid, or OCA, a novel bile acid analog and first-in-class agonist of the farnesoid X receptor, or FXR, as well as planned 2015 milestones and other general business updates. OCA is currently being developed for the treatment of several chronic liver diseases, including primary biliary cirrhosis, or PBC, nonalcoholic steatohepatitis, or NASH, and primary sclerosing cholangitis, or PSC. The completion of PBC Program NDA and MAA filings planned in 1H15. The NASH Program Phase 3 program initiation planned in 1H15 and Japan Phase 2 trial data expected at the end of 2015. The PSC Program Biliary Atresia: Phase 2 initiation planned in 2H15 and INT-767: Phase 1 initiation planned for the end of 2015. Intercept ended 2014 with approximately $240M in cash and investments. For FY15, the company projects adjusted operating expenses in the range of $180M-$200M, which excludes stock-based compensation and other non-cash items. These expenses will support the clinical development program for OCA in PBC, NASH and PSC, expansion of our clinical, regulatory, medical affairs and commercial infrastructure in the United States and Europe, expansion of OCA manufacturing activities, as well as advancement of INT-767 and other preclinical pipeline programs. Adjusted operating expense, as presented above, is a non-GAAP financial measure. The company anticipates that stock-based compensation expense will represent the most significant non-cash item that is excluded in adjusted operating expenses as compared to operating expenses under GAAP.
08:07 EDTADTADT Corp. downgraded at Morgan Stanley
As previously reported, Morgan Stanley downgraded ADT Corp to Underweight from Equal Weight. The firm downgraded shares based on rich valuation and a long cautious view on the home security market. Price target lowered to $34 from $36.
07:33 EDTAMBAAmbarella price target raised to $65 from $55 at Barrington
Subscribe for More Information
06:45 EDTADTADT Corp. downgraded to Underweight from Equal Weight at Morgan Stanley
Subscribe for More Information
05:52 EDTCHTRCharter initiated with an Outperform at Wells Fargo
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use